Rethinking the use of radiation and chemotherapy after radical hysterectomy: a clinical-pathologic analysis of a Gynecologic Oncology Group/Southwest Oncology Group/Radiation Therapy Oncology Group trial

被引:151
作者
Monk, BJ
Wang, JM
Im, S
Stock, RJ
Peters, WA
Liu, PY
Barrett, RJ
Berek, JS
Souhami, L
Grigsby, PW
Gordon, W
Alberts, DS
机构
[1] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Div Gynecol Oncol, Dept Obstet & Gynecol,Irvine Med Ctr, Orange, CA 92868 USA
[2] Roswell Pk Canc Inst, Gynecol Oncol Grp, State & Data Ctr, Buffalo, NY 14263 USA
[3] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
[4] USN, Med Ctr, Dept Pathol, Portsmouth, VA 23708 USA
[5] USN, Med Ctr, Dept Obstet & Gynecol, Portsmouth, VA 23708 USA
[6] Univ Washington, Seattle, WA 98104 USA
[7] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[8] Piedmont Gynecol Oncol, Winston Salem, NC 27103 USA
[9] Univ Calif Los Angeles, David Geffen Sch Med, Div Gynecol Oncol, Dept Obstet & Gynecol, Los Angeles, CA 90095 USA
[10] McGill Univ, Div Radiat Oncol, Dept Oncol, Montreal, PQ H3A 2T5, Canada
[11] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
[12] Deke Skayton Canc Ctr, Dept Radiotherapy, Webster, TX 77598 USA
[13] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA
关键词
cisplatin; radiation; radiosensitization; radical hysterectomy;
D O I
10.1016/j.ygyno.2004.11.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To retrospectively analyze data from a previously reported randomized trial of either pelvic radiation (RT) or RT + chemotherapy (CT) in patients undergoing radical hysterectomy and pelvic lymphadenectomy with positive pelvic lymph nodes, parametrial involvement, or surgical margins; to explore associations between RT + CT; and to investigate histopathologic and clinical factors which might be predictive of recurrence. Methods. Histopathologic sections from biopsies and hysterectomies and clinical data were reviewed from patients with stage IA2, III, or IIA cervical cancer treated with RT or RT + CT (cisplatin 70 mg/m(2) plus fluorouracil 1000 mg/m(2) every 3 weeks for four cycles). A univariate analysis was performed because the relatively small sample size limited the interpretation of a multivariate analysis. Results. Of the 268 enrolled women, 243 (RT = 116; RT + CT = 127) were evaluable. The beneficial effect of adjuvant CT was not strongly associated with patient age, histological type, or tumor grade. The prognostic significance of histological type, tumor size, number of positive nodes, and parametrial extension in the RT group was less apparent when CT was added. The absolute improvement in 5-year survival for adjuvant CT in patients with tumors <= 2 cm was only 5% (77% versus 82%), while for those with tumors > 2 cm it was 19% (58% versus 77%). Similarly, the absolute 5-year survival benefit was less evident among patients with one nodal metastasis (79% versus 83%) than when at least two nodes were positive (55% versus 75%). Conclusions. In this exploratory, hypothesis-generating analysis, adding CT to RT after radical hysterectomy, appears to provide a smaller absolute benefit when only one node is positive or when the tumor size is < 2 cm. Further study of the role of CT after radical hysterectomy in patients with a low risk of recurrence may be warranted. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:721 / 728
页数:8
相关论文
共 17 条
[1]   Intent-to-treat analysis of stage Ib and IIa cervical cancer in the United States: Radiotherapy or surgery 1988-1995 [J].
Brewster, WR ;
Monk, BJ ;
Ziogas, A ;
Anton-Culver, H ;
Yamada, SD ;
Berman, ML .
OBSTETRICS AND GYNECOLOGY, 2001, 97 (02) :248-254
[2]   PROSPECTIVE SURGICAL PATHOLOGICAL-STUDY OF DISEASE-FREE INTERVAL IN PATIENTS WITH STAGE IB SQUAMOUS-CELL CARCINOMA OF THE CERVIX - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
DELGADO, G ;
BUNDY, B ;
ZAINO, R ;
SEVIN, BU ;
CREASMAN, WT ;
MAJOR, F .
GYNECOLOGIC ONCOLOGY, 1990, 38 (03) :352-357
[3]   Radical hysterectomy for stage IB1 vs IB2 carcinoma of the cervix: Does the new staging system predict morbidity and survival? [J].
Finan, MA ;
DeCesare, S ;
Fiorica, JV ;
Chambers, R ;
Hoffman, MS ;
Kline, RC ;
Roberts, WS ;
Cavanagh, D .
GYNECOLOGIC ONCOLOGY, 1996, 62 (02) :139-147
[4]   New developments in the treatment of invasive cervical cancer [J].
Im, SS ;
Monk, BJ .
OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA, 2002, 29 (04) :659-+
[5]   FIGO STAGE, HISTOLOGY, HISTOLOGIC GRADE, AGE AND RACE AS PROGNOSTIC FACTORS IN DETERMINING SURVIVAL FOR CANCERS OF THE FEMALE GYNECOLOGICAL SYSTEM - AN ANALYSIS OF 1973-87 SEER CASES OF CANCERS OF THE ENDOMETRIUM, CERVIX, OVARY, VULVA, AND VAGINA [J].
KOSARY, CL .
SEMINARS IN SURGICAL ONCOLOGY, 1994, 10 (01) :31-46
[6]   PRETREATMENT AND TREATMENT FACTORS ASSOCIATED WITH IMPROVED OUTCOME IN SQUAMOUS-CELL CARCINOMA OF THE UTERINE CERVIX - A FINAL REPORT OF THE 1973 AND 1978 PATTERNS OF CARE STUDIES [J].
LANCIANO, RM ;
WON, M ;
COIA, LR ;
HANKS, GE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (04) :667-676
[7]   EXTENT OF DISEASE AS AN INDICATION FOR PELVIC RADIATION FOLLOWING RADICAL HYSTERECTOMY AND BILATERAL PELVIC LYMPH-NODE DISSECTION IN THE TREATMENT OF STAGE-IB AND IIA CERVICAL-CARCINOMA [J].
MONK, BJ ;
CHA, DS ;
WALKER, JL ;
BURGER, RA ;
RAMSINGHANI, NS ;
MANETTA, A ;
DISAIA, PJ ;
BERMAN, ML .
GYNECOLOGIC ONCOLOGY, 1994, 54 (01) :4-9
[8]   PROGNOSTIC-SIGNIFICANCE OF HUMAN PAPILLOMAVIRUS DNA IN VULVAR CARCINOMA [J].
MONK, BJ ;
BURGER, RA ;
LIN, F ;
PARHAM, G ;
VASILEV, SA ;
WILCZYNSKI, SP .
OBSTETRICS AND GYNECOLOGY, 1995, 85 (05) :709-715
[9]   EARLY CERVICAL-CARCINOMA - ARE 2 TREATMENTS BETTER THAN ONE [J].
MORRIS, M .
GYNECOLOGIC ONCOLOGY, 1994, 54 (01) :1-3
[10]  
MORROW CP, 1980, GYNECOL ONCOL, V10, P105, DOI 10.1016/0090-8258(80)90071-2